

Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

1. (currently amended) A method of screening for potential vaccine targets for infectious diseases, comprising:

(a) identifying human gene products selected from the group consisting of: human gene products which are upregulated by a factor of 9 or greater during viral or mycobacterial infection and human gene products which are expressed only during viral or mycobacterial infection;

(b) screening said human gene products for an immune a-cytotoxic T lymphocyte (CTL) response in humans;

wherein said immune response is selected from the group consisting of: antibody response, cytotoxic T lymphocyte (CTL) response, T helper response, inflammation, and cytokine production, and wherein said gene products which induce an immune a-CTL response in humans are potential vaccine targets for infectious diseases during which such upregulation or expression occurs.

2. (previously presented) The method of claim 1, wherein said human gene products which are upregulated by a factor of 9 or greater are expressed at a lower level in uninfected cells than in infected cells of the same type.

3. (previously presented) The method of claim 1, wherein said human gene products which are upregulated are not expressed at all in uninfected cells of the same type.

4. (original) The method of claim 1, wherein said infection is infection with human immunodeficiency virus (HIV).

5. (canceled)

6. (previously presented) The method of claim 1, wherein said human gene products of (a) are identified using ordered microarrays of nucleic acids.

7. (previously presented) The method of claim 1, wherein said human gene products of (a) are identified using subtractive hybridization.

8-23. (canceled)

24. (new) The method of claim 1, wherein said human gene products result from a mycobacterial infection.

25. (new) The method of claim 1, wherein said human gene products result from a viral infection.

26. (new) The method of claim 1, wherein said immune response is an antibody response.

27. (new) The method of claim 1, wherein said immune response is a CTL response.

28. (new) The method of claim 1, wherein said immune response is a T helper response.

29. (new) The method of claim 1, wherein said immune response is inflammation.

30. (new) The method of claim 1, wherein said immune response is cytokine production.